Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Rising Debt ⢠Persistent Cash Burn IBRX has strong near-term liquidity and gross margins, but escalating debt, negative equity, persistent cash burn, and steep losses make it a high-risk investment despite lower quarterly burn.
Price Behavior
Key Price Behavior Insights: ⢠Support holding ⢠Resistance tested ⢠Volatile pullback Support Level: $7.55â$7.60 Resistance Level: $8.40 IBRX is cautiously constructive over the last month above $7.55â$7.60 support, but needs a sustained break above $8.40 to confirm renewed upside amid volatility.
Sentiment & News
Key News Insights: ⢠Institutional Buying ⢠Clinical Catalysts ⢠Legal Overhang ImmunityBio gains institutional backing and leadership momentum, but upcoming clinical data and class-action risk remain key stock catalysts.
AI Summary
IBRX is an early commercial oncology story whose rapid ANKTIVA growth and January 2027 FDA label-expansion decision offer meaningful upside, but investors should prioritize evidence that sales can materially reduce cash burn and support $1.23B of debt before underwriting a durable rerating.
Description
ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines targeting cancers and infectious diseases. The company applies multiple immunotherapy and cell therapy approachesâincluding engineered cytokine fusion proteins, synthetic immunomodulators, and both natural killer and T-cell platformsâand has candidates in Phase II/III trials for solid and liquid tumors (for example, bladder, pancreatic and lung cancers) as well as antiviral programs for pathogens such as SARS-CoV-2 and HIV. It maintains research collaborations and licensing arrangements with U.S. government institutes and several biopharma partners and is headquartered in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 2 | Mar 9 | IBRX | ImmunityBio, Inc. | ImmunityBio posted ~700% YoY product-revenue growth, secured EU conditional approval and Saudi accelerated approval, and has multiple imminent clinical/label catalysts plus an investor update on 2026-03-03; the share price has climbed ~66% over 21 days and trades well above its 21âday SMA, positioning it as a highârisk but potent short-term momentum play. | Closed | -19.1% |
| Feb 19 | Feb 26 | IBRX | ImmunityBio, Inc. | Multiple recent regulatory wins (EU conditional approval for ANKTIVA+BCG on 2026-02-18, Saudi approval, FDA Type B meeting) plus an EU commercialization deal and accelerating product revenue (~$38M quarter) have driven a >200% month-long rally; momentum remains strong into further catalyst and financing headlines despite high risk. | Closed | +10.9% |
| Jan 16 | Jan 23 | IBRX | ImmunityBio, Inc. | ImmunityBio is a hot idea driven by accelerating commercial revenue growth (700% annual increase in 2025), regulatory approvals expanding markets, positive clinical data mid-January 2026, nearly doubled stock price in past month, despite ongoing financial risks. | Closed | +16.9% |